The risk of fraud within the Australian health, pharmaceuticals and medical devices sectors is significant,but more effective legal and regulatory responses than currently exist may be required for its detection and prevention. Looking at successful models from overseas jurisdictions may be of value. In particular, enhanced whistleblower protections and the qui tam litigation mechanism in the United States offer models for more effective anti-fraud measures. The model appears viable for local adaptation, but some legal, structural and cultural issues may need consideration and further research. This paper adopts the hypothesis that there is nothing intrinsic to the Australian legal system that would prevent the adoption of such mechanisms in Australia, and assesses the potential for these reforms to be introduced there.
|Number of pages||10|
|Journal||World Review of Business Research|
|Publication status||Published - 2012|